| Autor: |
Turik, Michael A, Zeckel, Michael L |
| Zdroj: |
Expert Opinion on Investigational Drugs; September 1995, Vol. 4 Issue: 9 p889-891, 3p |
| Abstrakt: |
New therapeutic options are required to address the issue of Gram-positive resistance which is currently emerging. Today, the glycopeptides vancomycin and teicoplanin are the clinician's last weapons against many serious pathogens, including MRSA (methicillin-resistant S. aureus), MRSE (methicillin-resistant S. epidermidis) and penicillin- and 3rd generation cephalosporin-resistant S. pneumoniae. The development of vancomycin resistance in enterococci has many ramifications, including the possible future absence of effective therapy against a pathogen which is becoming increasingly important in nosocomial infections; and the possibility that this resistance may be transferred to other, more virulent Gram-positive organisms. This symposium was designed to address some of these issues, and the principal findings are summarised in this update. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
